1. Cimolai, N. (2013). The potential and promise of mefenamic acid. Expert Review of Clinical Pharmacology, 6(3), 289–305.
2. Conroy, M. C., Randinitis, E. J., & Turner, J. L. (1991). Pharmacology, pharmacokinetics, and therapeutic use of meclofenamate sodium. Clinical Journal of Pain, 7(Suppl 1), S44–S48.
3. Delgado, J., Simonin, G., Servier, C., Garcia, R., & Yoma, J. (1984). Tolfenamic acid and mefenamic acid in the treatment of primary dysmenorrhoea. Pharmacology & Toxicology, 75(Suppl 2), 89–91.
4. Dupre, M., Ehrich, E., Van Hecken, A., Depeieire, J., Dallob, A., Wong, P., et al. (2000). Pharmacokinetics, COX-2 specificity and tolerability of supratherapeutic doses of rofecoxib in humans. European Journal of Clinical Pharmacology, 56, 167–174.
5. Horng, H., & Benet, L. Z. (2013). The nonenzymatic reactivity of the acyl-linked metabolites of mefenamic acid toward amino and thiol functional group bonucleophiles. Drug Metabolism and Disposition, 41, 1923–1933.